Context Therapeutics Inc. - Common Stock — Bilan (NASDAQ:CNTX) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Total de l'actif 51.31 M37.97 M16.06 M98.13 M68.49 M Total du passif 3.03 M3.21 M4.19 M2.86 M8.02 M Total des capitaux propres 48.27 M34.76 M11.87 M95.27 M60.47 M Total du passif et des capitaux propres 51.31 M37.97 M16.06 M98.13 M68.49 M Dette totale 0———— Dette nette -49.64 M————

Nouvelles

Pourquoi les actions de GH Research sont échangées à la hausse de 18% ; Voici 20 actions qui bougent avant l'ouverture du marché | Benzinga France

Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - BioAtla (NASDAQ:BCAB), ChowChow Cloud Internatio (AMEX:CHOW)

This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - AirJoule Technologies (NASDAQ:AIRJ), BlackSky Technology (NYSE:BKSY)

Step Pharma appoints Karen Smith as chief medical officer

This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Context Therapeutics (NASDAQ:CNTX), Absci (NASDAQ:ABSI)

Rare Stock Picks In June 2025 - From 26 Discerning Analysts

Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX)

Citizens JMP affirms $4 price target on Context Therapeutics stock

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Citizens JMP highlights key ASCO presentations

Centrexion Therapeutics stock hits 52-week low at $0.55

Citizens JMP highlights bispecific antibodies progress